Evaluation of NG-Test Carba 5 for Rapid Phenotypic Detection and Differentiation of Five Common Carbapenemase Families: Results of a Multicenter Clinical Evaluation
Stephen G. Jenkins, Nathan A. Ledeboer, Lars F. Westblade, Carey‐Ann D. Burnham, Matthew L. Faron, Yehudit Bergman, Rebecca Yee, Brian Mesich, Derek Gerstbrein, Meghan A. Wallace, Amy Robertson, Kathy Fauntleroy, Anna S. Klavins, Rianna Malherbe, André Hsiung, Patricia J. Simner
Abstract
NG-Test Carba 5 is a rapid in vitro multiplex immunoassay for the phenotypic detection and differentiation of five common carbapenemase families (KPC, OXA-48-like, VIM, IMP, and NDM) directly from bacterial colonies. The assay is simple to perform and has recently received U.S. Food and Drug Administration clearance. A method comparison study was performed at geographically diverse medical centers ( n = 3) in the United States, where 309 Enterobacterales and Pseudomonas aeruginosa isolates were evaluated by NG-Test Carba 5 (NG Biotech, Guipry, France), the Xpert Carba-R assay (Cepheid, Inc.